Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Information source: Alcon Research
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacterial Conjunctivitis
Intervention: Polytrim or similar (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Alcon Research
Official(s) and/or principal investigator(s):
Steven J. Lichtenstein, M.D., Principal Investigator, Affiliation: Investigator / Contact
Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora
Official title: Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Study design: Non-Randomized, Single Blind, Historical Control, Parallel Assignment
Primary outcome: Susceptability changes in specified bacteria in the nasal cavity, oropharynx or skin when measured
Minimum age: 1 Year.
Maximum age: 13 Years.
- Patients from 1 to 13 years of age that have diagnosis of bacterial conjunctivitis in
either or both eyes (for < 3 days duration) based on clinical observation; matched
- Cannot have had bacterial conjunctivitis symptoms as reported by parent for > 2 days
Locations and Contacts
Multiple Locations, Fort Worth, Texas 76134, United States
Starting date: April 2006
Last updated: September 10, 2007